CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers
Conditions: Cervical Cancer; Anal Cancer; Head and Neck Cancers; Other Solid Tumors Interventions: Drug: CRTE7A2-01 TCR-T cell therapy Sponsors: Corregene Biotechnology Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia
Conditions: Hypoalbuminemia; Hepatic Cirrhosis Interventions: Drug: OsrHSA; Drug: Plasbumin ®-20 Sponsors: Healthgen Biotechnology Corp. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Phase 2a Study to Evaluate IcBD-01 Enema in Active Ulcerative Colitis Patients
Conditions: Ulcerative Colitis Interventions: Drug: CBD, synthetic form; Drug: Placebo Sponsors: CannaMore Biotechs Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Phanes Therapeutics' PT217 Granted Fast Track Designation by the FDA
SAN DIEGO, April 8, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the U.S. Food and Drug Administration (FDA) has... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 8, 2024 Category: Pharmaceuticals Source Type: clinical trials
The PredictPlusPrevent Study
Conditions: Depression; Anxiety Disorders Interventions: Behavioral: Predictplusprevent intervention; Other: Psychoeducational intervention Sponsors: The Mediterranean Institute for the Advance of Biotechnology and Health Research Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2024 Category: Research Source Type: clinical trials
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
Conditions: Systemic Lupus Erythematosus; Lupus Nephritis; Autoimmune Diseases; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Granulomatous Polyangiitis; Microscopic Polyangiitis; Systemic Sclerosis; Idiopathic Inflammatory Myopathies; Sjogren ' s Syndrome Interventions: Biological: CD19- BCMA CAR-T cells Sponsors: Essen Biotech Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
The Study is Being Conducted to to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of Serplulimab Injection (HLX10) and HLX04 With or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
Conditions: Carcinoma, Hepatocellular Interventions: Drug: HLX53 (1000mg); Drug: HLX53 (2000mg); Drug: HLX10; Drug: HLX04; Other: Placebo Sponsors: Shanghai Henlius Biotech Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 With or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
Conditions: Carcinoma, Hepatocellular Interventions: Drug: HLX53 (1000mg); Drug: HLX53 (2000mg); Drug: HLX10; Drug: HLX04; Other: Placebo Sponsors: Shanghai Henlius Biotech Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
Sequential Vaccination of Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains From Different Manufacturers
Conditions: Poliomyelitis Interventions: Biological: sIPV Sponsors: Sinovac Biotech Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
Study to Assess Effects of Pasteurized Akkermansia Muciniphila vs Placebo in Participants With Diarrhea-predominant IBS
Conditions: Diarrhea-Predominant Irritable Bowel Syndrome Interventions: Dietary Supplement: Pasteurized Akkermansia muciniphila (pAKK); Dietary Supplement: Placebo Sponsors: A-Mansia Biotech S.A.; Vedic Lifesciences Pvt. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
Conditions: Acute Lymphoblastic Leukemia,B-Cell; Non-hodgkin Lymphoma,B Cell Interventions: Biological: CD19-BAFF Targeted CAR T-cells Sponsors: Zhejiang University; Shanghai YaKe Biotechnology Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
Immunogenicity and Safety of One Dose of HPV Vaccine
Conditions: Human Papillomavirus Vaccines Interventions: Biological: HPV vaccine Sponsors: Xiamen Innovax Biotech Co., Ltd Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
First Patient Dosed in Phase 2a Clinical Trial of a First-in-Class Regenerative Cell Therapy for Patients with End-Stage Liver Disease
PITTSBURGH, April 2, 2024. LyGenesis, a clinical-stage biotechnology company developing cell therapies for large unmet medical needs, announced today that the first patient has been dosed in their Phase 2a clinical trial... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 2, 2024 Category: Pharmaceuticals Source Type: clinical trials
To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension
Conditions: Difficult to Control Hypertension Interventions: Drug: MANP; Other: Placebo Matched control Sponsors: E-Star BioTech, LLC; Mayo Clinic; PPD Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
ADC189 Tablets on Influenza A Virus Infection/Influenza B Virus Infection
Conditions: Safety Issues; Effect of Drug Interventions: Drug: 15 mg ADC189; Drug: 45 mg ADC189; Drug: Placebo Sponsors: Jiaxing AnDiCon Biotech Co.,Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
